Cryoport (CYRX) Set to Report Q4 FY2025 Earnings After the Bell – Here’s What to Expect
Consistency Ratings
| Metric | Q4 FY2025 Est | Q4 FY2024 Actual | YOY Change |
|---|---|---|---|
| Net worth | ~$40–50M | ~$59.5M | ~-24% |
| EPS (Non-GAAP) | – | – | Watching the money burn |
| Effective Clinical Programs Supported | Looking for stability | – | The leading key indicator |
Analyst consensus: Strong Buy (9 analysts). Average price target: $12.83 compared to the current price of $8.21.
Key metrics to watch
1. Biopharma Logistics revenue and operating system calculation
Cryoport’s main value is the number of CGT clinical programs that use its cold chain services. When programs go from Phase 1 to Phase 2 to commercial launch, the revenue per program increases dramatically. If the programs fail or are abandoned, that income disappears completely. The number of active programs – and especially how many are in the later stages of testing or commercialization – is a very important indicator of future revenue. Any stability or growth in this metric would be a positive signal after the painful period of the CGT industry’s downturn.
2. FY2025 Full Year Revenue vs. Average $177M
The FY2025 annual revenue estimate of $177.12M represents a sharp 22% drop from FY2024’s $228.39M – but the TTM figure through September 2025 was $243.8M, which makes up the difference. Either Q4 expectations are too low (perhaps reflecting known contract losses or program terminations), or the annual average is too old. Clarifying this gap is important. If actual FY2025 revenue comes in above $177M, it could represent a positive material surprise relative to the underlying depression.
3. Disability Expenses
The purchase of CRYOPDP in 2021 – the European temperature control network – was carried out at a high price and was a huge drain on the company’s finances, contributing to large impairment costs (FY2024 GAAP net loss was $114.76M mainly due to write-downs). Last year, the company sold CRYOPDP to DHL Group.
4. Free Cash Flow and Stability
Cryoport burned $33.58M in free cash flow in FY2024, and the GAAP loss was significant. Investors are very focused on the airline – how much money does the company have, and at what rate? Any guidance that suggests the company needs to raise capital can be very negative. A credible path towards FCF breakdown in FY2026 would be one of the most constructive things management can say tonight.
5. FY2026 Outlook and CGT Pipeline Commentary
Management’s forward guidance and voice in the CGT market pipeline will dictate how the stock trades next quarter. Cryoport is a bet on the long-term growth of cell and gene therapy — a large market that has been slower to trade than early investors expected. Any details on an upcoming commercial product launch that will use Cryoport’s infrastructure, a new customer win, or a regulatory approval expected in 2026 would be a clear indication of why the stock could diverge from here.
Situational Analysis
| The situation | Net worth | Burning of Money | CGT programs | Stock reaction |
|---|---|---|---|---|
| **Bull** | >$55M Q4; FY over $210M | Shrinking towards cracking | Active count is stable/growing | +15% to +25% |
| **Base** | ~$45–52M Q4; FY ~$185–200M | A modest improvement | Equation of a flat system | -5% to +10% |
| **Bear** | <$42M Q4; FY under $180M | A bearish or bullish signal | The number of the program is decreasing | -18% to 28% |
Bull case: Q4 revenue comes in at more than $55M, the full year significantly surpassing the disappointing $177M estimate, and management points to a certain pipeline of commercial CGT launches in 2026 that will improve meaningful revenue growth. Free cash flow is improving materially. The stock, hit hard, is starting to recover in the $10–12 range.
Base case: Revenues are roughly in line with estimates, and management is giving optimistic comments on the CGT pipeline without specific catalysts. The stock is holding steady near current levels – a relief given that any sign of risk could bring it down.
Bear case: Revenues are missing miserably, TTM-year-over-year variances are misaligned (Q4 was bad), and management signals that a cash increase may be needed. The stock breaks below the analyst’s low-level target of $7, testing levels where CGT’s infrastructure thesis has an effective rate of failure.
Context: Latest trends
Cryoport’s story is inextricably linked to the commercial side of the cell and gene therapy industry. In the early 2020s, CGT was the hottest place in biopharma – dozens of programs in trials coming to an end, many commercial approvals expected, and Cryoport positioned as an important playground for cold infrastructure. Investors bid the stock to $70+ on the assumption that all CGT commercial launches will generate long-term, high-quality logistics revenue for Cryoport.
What happened instead: clinical trial failure rates in CGT remained stubbornly high, manufacturing challenges delayed commercial release, and several high-profile programs (especially in gene editing) failed to reach the market or were discontinued altogether. At the same time, CryopDP’s acquisition of Cryoport – intended to create a global network of European logistics – proved to be more expensive to integrate than expected and caused a large write-down. The stock’s fall from $70+ to $8 reflects both the industry-wide CGT reset and company-specific execution concerns.
The long-term bull thesis is not dead. CGT remains a revolutionary medical technology, and Cryoport is truly the leading specialized cryogenic provider of these therapies. As the industry grows and more products reach commercial approval — CAR-T therapies, gene editing therapies, and next-generation cell therapies — Cryoport’s infrastructure becomes more valuable. The question is whether the company can survive the gap period with enough capital and operational discipline to be there when the tide comes. Tonight’s results will emphasize that the company is handling the turnaround well, or deepen concerns that financial pressures are mounting.
The earnings call starts after the market closes. Follow AlphaStreet for live coverage and analysis of post-earnings results.
Source: StockAnalysis, AlphaStreet Earnings Calendar. Estimates as of March 3, 2026. Consensus figures are estimated and subject to revision.
